Literature DB >> 3987541

Haemodynamic effects of intravenous felodipine in normotensive and hypertensive subjects.

H E Sluiter, F T Huysmans, T A Thien, R A Koene.   

Abstract

The effects of intravenous administration of a new calcium antagonist, felodipine, were studied in healthy subjects and hypertensive patients. Felodipine infused at a rate of 0.01 mg/min in 10 normotensive volunteers caused gradual haemodynamic and hormonal changes compatible with a direct vasodilatory mechanism of action; it also had a diuretic and natriuretic effect. When infused at a mean dose of 0.02 mg/kg bodyweight over 20 to 120 minutes in 7 patients with a hypertensive emergency, felodipine caused a rapid reduction in blood pressure with a maximal fall in mean arterial pressure of 30.4 +/- 7.3% (mean +/- 1 SD) in 30 minutes. No serious side effects were observed. The haemodynamic effectiveness of an infusion rate of 0.01 mg/min was confirmed in a pilot study of 5 patients with refractory hypertension. On the basis of these findings, a schedule for the treatment of acute hypertension with intravenous felodipine is proposed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987541     DOI: 10.2165/00003495-198500292-00025

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  25 in total

Review 1.  Vasodilator drugs in the treatment of hypertension.

Authors:  J Koch-Weser
Journal:  Arch Intern Med       Date:  1974-06

2.  Acute treatment of hypertension with nifedipine.

Authors:  F T Huysmans; T A Thien; H E Sluiter; R A Koene
Journal:  Neth J Med       Date:  1983       Impact factor: 1.422

3.  A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment.

Authors:  J A Koziol; D A Maxwell; M Fukushima; M E Colmerauer; Y H Pilch
Journal:  Biometrics       Date:  1981-06       Impact factor: 2.571

4.  Interaction of the antihypertensive drug felodipine with calmodulin.

Authors:  S L Bostróm; B Ljung; S Mårdh; S Forsen; E Thulin
Journal:  Nature       Date:  1981-08-20       Impact factor: 49.962

5.  Cerebral complications in the treatment of accelerated hypertension.

Authors:  J G Ledingham; B Rajagopalan
Journal:  Q J Med       Date:  1979-01

6.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

7.  Short-term effects of felodipine, a new dihydropyridine, in hypertension.

Authors:  O Andersson; C Bengtsson; D Elmfeldt; K Haglund; T Hedner; P Seideman; K H Sjöberg; E Strömgren; H Aberg; J Ostman
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

8.  Effect of calcium-antagonist and calmodulin-antagonist drugs on calmodulin-dependent contractions of chemically skinned vascular smooth muscle from rabbit renal arteries.

Authors:  V A Kreye; J C Rüegg; F Hofmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-06       Impact factor: 3.000

9.  Radioenzymatic assay of plasma adrenaline and noradrenaline: evidence for a catechol-O-methyltransferase (COMT) inhibiting factor associated with essential hypertension.

Authors:  J J Hoffmann; J J Willemsen; T Thien; T J Benraad
Journal:  Clin Chim Acta       Date:  1982-11-10       Impact factor: 3.786

10.  Nifedipine in the treatment of hypertension: report of a double-blind controlled trial.

Authors:  S Bayley; R J Dobbs; B F Robinson
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

View more
  10 in total

1.  Pharmacokinetics and hemodynamic and diuretic/natriuretic effects of felodipine administered as an extended-release tablet.

Authors:  B Hasselgren; O Rönn; B Edgar; P Johansson; B Wall
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

2.  Antihypertensive and biochemical effects of the dihydropyridine felodipine in the long term treatment of moderate to severe hypertension.

Authors:  H E Sluiter; F T Huysman; T A Thien; R A Koene
Journal:  Drugs       Date:  1987       Impact factor: 9.546

3.  Effects of felodipine and metoprolol on blood pressure, plasma renin, angiotensin II, aldosterone and catecholamines in hypertensive patients.

Authors:  P Lijnen; R Fagard; J Staessen; E Moerman; A De Schaepdryver; A Amery
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of felodipine. A summary.

Authors:  B Edgar; P Lundborg; C G Regårdh
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Haemodynamic, hormonal, and diuretic effects of felodipine in healthy normotensive volunteers.

Authors:  H E Sluiter; F T Huysmans; T A Thien; H J van Lier; R A Koene
Journal:  Drugs       Date:  1985       Impact factor: 9.546

6.  Hemodynamic interactions between diuretics and calcium antagonists in the treatment of hypertensive patients.

Authors:  S Di Somma; V Liguori; M Petitto; G Cavallotti; S Savonitto; O de Divitiis
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

7.  Natriuretic and diuretic effects of felodipine and hydrochlorothiazide after single and repeated doses.

Authors:  B Hasselgren; P Johansson
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

8.  Acute diuretic/natriuretic properties of felodipine in man.

Authors:  B Edgar; B Bengtsson; D Elmfeldt; P Lundborg; G Nyberg; S Raner; O Rönn
Journal:  Drugs       Date:  1985       Impact factor: 9.546

9.  Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.

Authors:  H E Sluiter
Journal:  Drugs       Date:  1987       Impact factor: 9.546

10.  A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.

Authors:  Laura Maria Fuhr; Fatima Zahra Marok; Maximilian Mees; Felix Mahfoud; Dominik Selzer; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2022-07-15       Impact factor: 6.525

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.